The recent launch of a multi-agency joint task force by China’s State Administration for Market Regulation (SAMR) to investigate claims regarding formamide in infant diapers is a necessary and significant move. In response to media reports from the Economic Information Daily—which suggested that certain diaper products from brands such as Huggies, Babycare, and Bibabebe tested positive for the chemical—authorities are now conducting a full-chain verification, involving the Ministry of Industry and Information Technology, the National Health Commission, and the National Disease Control and Prevention Administration.
Understanding the Context
The controversy originated from an investigative report alleging that formamide, a synthetic compound, was detected in specific diaper products. The report further claimed that the substance had been found in some infants’ blood and urine samples, attributing recurring symptoms like diaper rash and skin irritation to these products. For parents, the issue is particularly sensitive; formamide is classified internationally as a reproductive toxicant and a “substance of very high concern” (SVHC) under European Union regulations. While legitimate manufacturing processes do not intentionally add formamide, any presence is typically considered a residual trace that, in prolonged, airtight contact with an infant’s skin, is viewed by health experts as a potential risk factor for irritation and long-term development.
Industry and Regulatory Response
The industry’s reaction has been swift but conflicting. All three brands named—Huggies, Babycare, and Bibabebe—have publicly denied the findings, citing their own third-party testing that showed “not detected” results for formamide across their product lines. Some companies have even signaled legal action against what they describe as “false, misleading, and malicious” information.
For the general public, the current situation highlights a significant “information gap” between laboratory-commissioned reports and company-provided safety audits. The government’s intervention aims to bridge this gap by establishing an authoritative, cross-departmental standard for verification. Authorities in cities like Shanghai, Hangzhou, and Tianjin have already begun onsite inspections of production links and raw materials to ensure comprehensive coverage.
Why This Matters
Public sensitivity toward infant product safety in China remains exceptionally high, largely due to historical precedents regarding consumer protection. The government’s decision to form a high-level task force underscores the priority placed on child safety and the need to restore market confidence. While we await the official findings, this investigation serves as a critical stress test for the transparency of the maternal and infant product industry. A definitive, government-backed conclusion will be essential not only to clarify the safety of the specific products in question but also to set a clearer, more rigorous compliance framework for the entire sector moving forward.
News source: https://peoplesdaily.pdnews.cn/china/er/30052460763